Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY.

Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, Ghigo E, Camacho-Hubner C, Pan K, Lavenberg J, Jönsson P, Hey-Hadavi JH.

Eur J Endocrinol. 2018 Dec 1;179(6):419-427. doi: 10.1530/EJE-18-0616.

PMID:
30325178
2.

Characterization of cyclic Cushing's disease using late night salivary cortisol testing.

Jahandideh D, Swearingen B, Nachtigall LB, Klibanski A, Biller BMK, Tritos NA.

Clin Endocrinol (Oxf). 2018 Sep;89(3):336-345. doi: 10.1111/cen.13758. Epub 2018 Jun 25.

PMID:
29873834
3.

Macimorelin as a Diagnostic Test for Adult GH Deficiency.

Garcia JM, Biller BMK, Korbonits M, Popovic V, Luger A, Strasburger CJ, Chanson P, Medic-Stojanoska M, Schopohl J, Zakrzewska A, Pekic S, Bolanowski M, Swerdloff R, Wang C, Blevins T, Marcelli M, Ammer N, Sachse R, Yuen KCJ.

J Clin Endocrinol Metab. 2018 Aug 1;103(8):3083-3093. doi: 10.1210/jc.2018-00665.

PMID:
29860473
4.

Medical Therapy for Cushing's Syndrome in the Twenty-first Century.

Tritos NA, Biller BMK.

Endocrinol Metab Clin North Am. 2018 Jun;47(2):427-440. doi: 10.1016/j.ecl.2018.01.006. Epub 2018 Apr 9. Review.

PMID:
29754642
5.

The current state of long-acting growth hormone preparations for growth hormone therapy.

Yuen KCJ, Miller BS, Biller BMK.

Curr Opin Endocrinol Diabetes Obes. 2018 Aug;25(4):267-273. doi: 10.1097/MED.0000000000000416. Review.

PMID:
29746309
6.

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults.

Johannsson G, Bidlingmaier M, Biller BMK, Boguszewski M, Casanueva FF, Chanson P, Clayton PE, Choong CS, Clemmons D, Dattani M, Frystyk J, Ho K, Hoffman AR, Horikawa R, Juul A, Kopchick JJ, Luo X, Neggers S, Netchine I, Olsson DS, Radovick S, Rosenfeld R, Ross RJ, Schilbach K, Solberg P, Strasburger C, Trainer P, Yuen KCJ, Wickstrom K, Jorgensen JOL; Growth Hormone Research Society.

Endocr Connect. 2018 Mar;7(3):R126-R134. doi: 10.1530/EC-18-0047. Epub 2018 Feb 26. Review.

7.

The UK Centre for Astrobiology: A Virtual Astrobiology Centre. Accomplishments and Lessons Learned, 2011-2016.

Cockell CS, Biller B, Bryce C, Cousins C, Direito S, Forgan D, Fox-Powell M, Harrison J, Landenmark H, Nixon S, Payler SJ, Rice K, Samuels T, Schwendner P, Stevens A, Nicholson N, Wadsworth J.

Astrobiology. 2018 Feb;18(2):224-243. doi: 10.1089/ast.2017.1713. Epub 2018 Jan 29.

8.

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.

Strasburger CJ, Mattsson A, Wilton P, Aydin F, Hey-Hadavi J, Biller BMK.

Eur J Endocrinol. 2018 Apr;178(4):321-329. doi: 10.1530/EJE-17-0996. Epub 2018 Jan 25.

9.

Health Care Burden in Patients With Adrenal Insufficiency.

Gunnarsson C, Ryan MP, Marelli C, Baker ER, Stewart PM, Johannsson G, Biller BMK.

J Endocr Soc. 2017 Apr 12;1(5):512-523. doi: 10.1210/js.2016-1064. eCollection 2017 May 1.

10.

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J; Pasireotide G2304 Study Group.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1. Epub 2017 Oct 12. Erratum in: Lancet Diabetes Endocrinol. 2018 Jan;6(1):e1.

PMID:
29032078
11.

Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly.

Fahlbusch R, Kleinberg D, Biller B, Bonert V, Buchfelder M, Cappabianca P, Carmichael J, Chandler W, Colao A, George A, Klibanski A, Knopp E, Kreutzer J, Kundurti N, Lesser M, Mamelak A, Pivonello R, Post K, Swearingen B, Vance ML, Barkan A.

Pituitary. 2017 Dec;20(6):668-675. doi: 10.1007/s11102-017-0832-8.

PMID:
28825168
12.

Bone microarchitecture and estimated bone strength in men with active acromegaly.

Silva PPB, Amlashi FG, Yu EW, Pulaski-Liebert KJ, Gerweck AV, Fazeli PK, Lawson E, Nachtigall LB, Biller BMK, Miller KK, Klibanski A, Bouxsein M, Tritos NA.

Eur J Endocrinol. 2017 Nov;177(5):409-420. doi: 10.1530/EJE-17-0468. Epub 2017 Aug 5.

PMID:
28780520
13.

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

Laver T, London CA, Vail DM, Biller BJ, Coy J, Thamm DH.

Vet Comp Oncol. 2018 Mar;16(1):E23-E29. doi: 10.1111/vco.12328. Epub 2017 Jun 15.

PMID:
28621057
14.

BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.

Geer EB, Shafiq I, Gordon MB, Bonert V, Ayala A, Swerdloff RS, Katznelson L, Lalazar Y, Manuylova E, Pulaski-Liebert KJ, Carmichael JD, Hannoush Z, Surampudi V, Broder MS, Cherepanov D, Eagan M, Lee J, Said Q, Neary MP, Biller BMK.

Endocr Pract. 2017 Aug;23(8):962-970. doi: 10.4158/EP171787.OR. Epub 2017 Jun 14.

PMID:
28614003
15.

Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.

Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Scaroni C, Ravichandran S, Kandra A, Biller BMK.

Endocrine. 2017 Jul;57(1):156-165. doi: 10.1007/s12020-017-1316-3. Epub 2017 Jun 9.

16.

Radiotherapy, Especially at Young Age, Increases the Risk for De Novo Brain Tumors in Patients Treated for Pituitary/Sellar Lesions.

Burman P, van Beek AP, Biller BM, Camacho-Hübner C, Mattsson AF.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):1051-1058. doi: 10.1210/jc.2016-3402.

PMID:
28359095
17.

Is GH dosing optimal in female patients with adult-onset GH deficiency? An analysis from the NordiNet® International Outcome Study.

Höybye C, Weber MM, Pournara E, Tønnes Pedersen B, Biller BMK.

Clin Endocrinol (Oxf). 2017 Jun;86(6):798-805. doi: 10.1111/cen.13330. Epub 2017 Apr 19.

PMID:
28306165
18.

Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians.

Geer EB, Ayala A, Bonert V, Carmichael JD, Gordon MB, Katznelson L, Manuylova E, Shafiq I, Surampudi V, Swerdloff RS, Broder MS, Cherepanov D, Eagan M, Lee J, Said Q, Neary MP, Biller BMK.

Pituitary. 2017 Aug;20(4):422-429. doi: 10.1007/s11102-017-0801-2.

PMID:
28275992
19.

Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.

Tritos NA, Chanson P, Jimenez C, King D, Jönsson PJ, Klibanski A, Biller BM.

Eur J Endocrinol. 2017 Feb;176(2):213-220. Epub 2016 Nov 15.

PMID:
27932529
20.

MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.

Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, Góth M, Olšovská V, Trejbalová L, Vadasz J, Fima E, Koren R, Amitzi L, Bidlingmaier M, Hershkovitz O, Hart G, Biller BMK.

Eur J Endocrinol. 2017 Mar;176(3):283-294. doi: 10.1530/EJE-16-0748. Epub 2016 Dec 8.

21.

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM.

Endocrine. 2016 Nov;54(2):516-523. Epub 2016 May 21.

22.

The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet® International Outcome Study.

Weber MM, Biller BM, Pedersen BT, Pournara E, Christiansen JS, Höybye C.

Clin Endocrinol (Oxf). 2017 Feb;86(2):192-198. doi: 10.1111/cen.13256. Epub 2016 Nov 21.

PMID:
27736009
23.

Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.

Tritos NA, Biller BM.

Pituitary. 2017 Feb;20(1):129-135. doi: 10.1007/s11102-016-0753-y. Review.

PMID:
27631335
24.

Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.

Stewart PM, Biller BM, Marelli C, Gunnarsson C, Ryan MP, Johannsson G.

J Clin Endocrinol Metab. 2016 Dec;101(12):4843-4850. Epub 2016 Sep 13.

PMID:
27623069
25.

Dopamine Agonists Can Reduce Cystic Prolactinomas.

Faje A, Chunharojrith P, Nency J, Biller BM, Swearingen B, Klibanski A.

J Clin Endocrinol Metab. 2016 Oct;101(10):3709-3715. Epub 2016 Jul 26.

PMID:
27459530
26.

2016 AAHA Oncology Guidelines for Dogs and Cats.

Biller B, Berg J, Garrett L, Ruslander D, Wearing R, Abbott B, Patel M, Smith D, Bryan C.

J Am Anim Hosp Assoc. 2016 Jul-Aug;52(4):181-204. doi: 10.5326/JAAHA-MS-6570. Epub 2016 Jun 3. Erratum in: J Am Anim Hosp Assoc. 2016 Nov/Dec;52(6):viii.

PMID:
27259020
27.

Complications of Cushing's syndrome: state of the art.

Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A.

Lancet Diabetes Endocrinol. 2016 Jul;4(7):611-29. doi: 10.1016/S2213-8587(16)00086-3. Epub 2016 May 10. Review.

PMID:
27177728
28.

Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.

Pellin MA, Wouda RM, Robinson K, Tsimbas K, Kurzman ID, Biller BJ, Vail DM.

Vet Comp Oncol. 2017 Sep;15(3):919-931. doi: 10.1111/vco.12232. Epub 2016 May 5.

PMID:
27146577
29.

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations.

Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, Chanson P, Chatelain P, Choong CS, Clemmons DR, Cohen LE, Cohen P, Frystyk J, Grimberg A, Hasegawa Y, Haymond MW, Ho K, Hoffman AR, Holly JM, Horikawa R, Höybye C, Jorgensen JO, Johannsson G, Juul A, Katznelson L, Kopchick JJ, Lee KO, Lee KW, Luo X, Melmed S, Miller BS, Misra M, Popovic V, Rosenfeld RG, Ross J, Ross RJ, Saenger P, Strasburger CJ, Thorner MO, Werner H, Yuen K.

Eur J Endocrinol. 2016 Jun;174(6):C1-8. doi: 10.1530/EJE-16-0111. Epub 2016 Mar 23.

30.

Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study.

Hamrahian AH, Yuen KC, Gordon MB, Pulaski-Liebert KJ, Bena J, Biller BM.

Pituitary. 2016 Jun;19(3):332-41. doi: 10.1007/s11102-016-0712-7.

PMID:
26897383
31.

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.

Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen J, Cianfarani S, Clayton P, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger D, Erfurth EM, Fuqua JS, Grimberg A, Haymond M, Higham C, Ho K, Hoffman AR, Hokken-Koelega A, Johannsson G, Juul A, Kopchick J, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Sorensen HT, Stochholm K, Strasburger C, Swerdlow A, Thorner M.

Eur J Endocrinol. 2016 Feb;174(2):P1-9. doi: 10.1530/EJE-15-0873. Epub 2015 Nov 12.

32.

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.

Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T, Hilliard A, Tian C, Sauter N, Biller BM, Bertagna X.

Pituitary. 2016 Apr;19(2):138-48. doi: 10.1007/s11102-015-0692-z.

34.

PATIENTS' PERCEPTION ON CLINICAL OUTCOME AND QUALITY OF LIFE AFTER A DIAGNOSIS OF CUSHING SYNDROME.

Papoian V, Biller BM, Webb SM, Campbell KK, Hodin RA, Phitayakorn R.

Endocr Pract. 2016 Jan;22(1):51-67. doi: 10.4158/EP15855.OR. Epub 2015 Oct 5.

PMID:
26437213
35.

Pregnancy outcomes in women with growth hormone deficiency.

Vila G, Akerblad AC, Mattsson AF, Riedl M, Webb SM, Hána V, Nielsen EH, Biller BM, Luger A.

Fertil Steril. 2015 Nov;104(5):1210-7.e1. doi: 10.1016/j.fertnstert.2015.07.1132. Epub 2015 Aug 6.

PMID:
26256649
36.

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society.

J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29.

37.

Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease.

Amlashi FG, Swearingen B, Faje AT, Nachtigall LB, Miller KK, Klibanski A, Biller BM, Tritos NA.

J Clin Endocrinol Metab. 2015 Oct;100(10):3770-7. doi: 10.1210/jc.2015-2107. Epub 2015 Jul 21.

PMID:
26196950
38.

Status of long-acting-growth hormone preparations--2015.

Høybye C, Cohen P, Hoffman AR, Ross R, Biller BM, Christiansen JS; Growth Hormone Research Society.

Growth Horm IGF Res. 2015 Oct;25(5):201-6. doi: 10.1016/j.ghir.2015.07.004. Epub 2015 Jul 14. Review.

PMID:
26187188
39.

Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.

Paoloni M, Mazcko C, Selting K, Lana S, Barber L, Phillips J, Skorupski K, Vail D, Wilson H, Biller B, Avery A, Kiupel M, LeBlanc A, Bernhardt A, Brunkhorst B, Tighe R, Khanna C.

PLoS One. 2015 Jun 19;10(6):e0129954. doi: 10.1371/journal.pone.0129954. eCollection 2015.

40.

Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients.

Javorsky BR, Carroll TB, Tritos NA, Salvatori R, Heaney AP, Fleseriu M, Biller BM, Findling JW.

Obes Surg. 2015 Dec;25(12):2306-13. doi: 10.1007/s11695-015-1681-z.

PMID:
25917980
41.

Hedgehog signaling is activated in canine transitional cell carcinoma and contributes to cell proliferation and survival.

Gustafson TL, Kitchell BE, Biller B.

Vet Comp Oncol. 2017 Mar;15(1):174-183. doi: 10.1111/vco.12149. Epub 2015 Apr 10.

PMID:
25864514
42.

Update on radiation therapy in patients with Cushing's disease.

Tritos NA, Biller BM.

Pituitary. 2015 Apr;18(2):263-8. doi: 10.1007/s11102-014-0615-4. Review.

PMID:
25359445
43.

Cushing's disease.

Tritos NA, Biller BM.

Handb Clin Neurol. 2014;124:221-34. doi: 10.1016/B978-0-444-59602-4.00015-0. Review.

PMID:
25248590
44.

Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency.

Dichtel LE, Yuen KC, Bredella MA, Gerweck AV, Russell BM, Riccio AD, Gurel MH, Sluss PM, Biller BM, Miller KK.

J Clin Endocrinol Metab. 2014 Dec;99(12):4712-9. doi: 10.1210/jc.2014-2830.

45.

Outcomes of proton therapy for patients with functional pituitary adenomas.

Wattson DA, Tanguturi SK, Spiegel DY, Niemierko A, Biller BM, Nachtigall LB, Bussière MR, Swearingen B, Chapman PH, Loeffler JS, Shih HA.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):532-9. doi: 10.1016/j.ijrobp.2014.06.068. Epub 2014 Sep 3.

PMID:
25194666
46.

Metronomic chemotherapy in veterinary patients with cancer: rethinking the targets and strategies of chemotherapy.

Biller B.

Vet Clin North Am Small Anim Pract. 2014 Sep;44(5):817-29. doi: 10.1016/j.cvsm.2014.05.003. Epub 2014 Jul 12. Review.

PMID:
25174901
47.

Contextualized analysis of a needs assessment using the Theoretical Domains Framework: a case example in endocrinology.

Lazure P, Bartel RC, Biller BM, Molitch ME, Rosenthal SM, Ross JL, Bernsten BD, Hayes SM.

BMC Health Serv Res. 2014 Jul 24;14:319. doi: 10.1186/1472-6963-14-319.

48.

Pituitary apoplexy: large surgical series with grading system.

Jho DH, Biller BM, Agarwalla PK, Swearingen B.

World Neurosurg. 2014 Nov;82(5):781-90. doi: 10.1016/j.wneu.2014.06.005. Epub 2014 Jun 8.

PMID:
24915069
49.

Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.

Tritos NA, Johannsson G, Korbonits M, Miller KK, Feldt-Rasmussen U, Yuen KC, King D, Mattsson AF, Jonsson PJ, Koltowska-Haggstrom M, Klibanski A, Biller BM.

J Clin Endocrinol Metab. 2014 Jun;99(6):2018-29. doi: 10.1210/jc.2014-1013. Epub 2014 Apr 2.

PMID:
24694339
50.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27.

PMID:
24533697

Supplemental Content

Loading ...
Support Center